June 13th 2025
Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.
Dr Kerin Adelson on Changes in Care Coordination Precipitated by OCM
Cancer Does Not Stop for COVID-19, but Reform Becomes a Challenge
Counties Experiencing Persistent Poverty Have Higher Cancer Mortality Rates
Dr Kashyap Patel Discusses COVID-19 Implications for PCOC® 2020